Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Monotherapy vs Dulaglutide in Japanese T2D
NCT03861052Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Primary completion
- Mar 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 52 weeks. Started May 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03861052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861052.